FR2941949B1 - Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met. - Google Patents

Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.

Info

Publication number
FR2941949B1
FR2941949B1 FR0900510A FR0900510A FR2941949B1 FR 2941949 B1 FR2941949 B1 FR 2941949B1 FR 0900510 A FR0900510 A FR 0900510A FR 0900510 A FR0900510 A FR 0900510A FR 2941949 B1 FR2941949 B1 FR 2941949B1
Authority
FR
France
Prior art keywords
cycloalkyl
triazolopyridazine
benzothiazoles
benzimidazoles
sulfanyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0900510A
Other languages
English (en)
French (fr)
Other versions
FR2941949A1 (fr
Inventor
Antonio Ugolini
Conception Nemecek
Sylvie Wentzler
Eric Bacque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0900510A priority Critical patent/FR2941949B1/fr
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to AU2010212231A priority patent/AU2010212231A1/en
Priority to MX2011008312A priority patent/MX2011008312A/es
Priority to CN2010800150530A priority patent/CN102388029A/zh
Priority to CA2751525A priority patent/CA2751525A1/fr
Priority to EP10708277A priority patent/EP2393790A1/fr
Priority to MA34147A priority patent/MA33102B1/fr
Priority to SG2011056470A priority patent/SG173558A1/en
Priority to PCT/FR2010/050177 priority patent/WO2010089506A1/fr
Priority to KR1020117020676A priority patent/KR20110126660A/ko
Priority to EA201171010A priority patent/EA201171010A1/ru
Priority to BRPI1011354A priority patent/BRPI1011354A2/pt
Priority to JP2011548750A priority patent/JP2012517407A/ja
Priority to ARP100100316A priority patent/AR075248A1/es
Priority to TW099103558A priority patent/TW201040187A/zh
Priority to UY0001032419A priority patent/UY32419A/es
Publication of FR2941949A1 publication Critical patent/FR2941949A1/fr
Publication of FR2941949B1 publication Critical patent/FR2941949B1/fr
Application granted granted Critical
Priority to IL214407A priority patent/IL214407A0/en
Priority to CO11099121A priority patent/CO6400222A2/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR0900510A 2009-02-06 2009-02-06 Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met. Expired - Fee Related FR2941949B1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR0900510A FR2941949B1 (fr) 2009-02-06 2009-02-06 Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
JP2011548750A JP2012517407A (ja) 2009-02-06 2010-02-04 ６−（６−ｏ−シクロアルキル−または６−ｎｈ−シクロアルキル−トリアゾロピリダジン−スルファニル）ベンゾチアゾールおよびベンゾイミダゾールの誘導体、この調製、薬物としてのこの使用、ならびにｍｅｔ阻害薬としてのこの使用
MX2011008312A MX2011008312A (es) 2009-02-06 2010-02-04 Derivados de 6-(6-o-cicloalquil o de 6-nh-cicloalquil-triazolopiri dazina-sulfanil) benzotiazoles y bencimidazoles: preparacion, aplicacion como medicamentos y uso como inhibidores de met.
CA2751525A CA2751525A1 (fr) 2009-02-06 2010-02-04 Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met
EP10708277A EP2393790A1 (fr) 2009-02-06 2010-02-04 Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met
MA34147A MA33102B1 (fr) 2009-02-06 2010-02-04 Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met
SG2011056470A SG173558A1 (en) 2009-02-06 2010-02-04 Derivatives of 6-(6-o-cycloalkyl or 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
PCT/FR2010/050177 WO2010089506A1 (fr) 2009-02-06 2010-02-04 Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met
BRPI1011354A BRPI1011354A2 (pt) 2009-02-06 2010-02-04 derivados de 6-(6-0-ciclo alquil ou 6-nh-ciclo alquil-triazolo piridazina sulfanil) benzotiazóis e benzimadazóis: preparo, aplicação como medicamentos e utilização como inibidores de met
EA201171010A EA201171010A1 (ru) 2009-02-06 2010-02-04 Производные 6-(6-o-циклоалкил- или 6-nh-циклоалкилтриазолопиридазинсульфанил)бензотиазолов и бензимидазолов: способ получения, применение в качестве лекарственных средств и применение в качестве ингибиторов met
AU2010212231A AU2010212231A1 (en) 2009-02-06 2010-02-04 Derivatives of 6-(6-O-cycloalkyl or 6-NH-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as MET inhibitors
CN2010800150530A CN102388029A (zh) 2009-02-06 2010-02-04 6-(6-o-环烷基-或6-nh-环烷基-三唑并哒嗪-硫基)苯并噻唑和苯并咪唑的衍生物、其制备方法、其作为药物的用途以及其作为met抑制剂的用途
KR1020117020676A KR20110126660A (ko) 2009-02-06 2010-02-04 6-(6-ｏ-시클로알킬 또는 6-ｎｈ-시클로알킬-트리아졸로피리다진-술파닐) 벤조티아졸 및 벤즈이미다졸의 유도체, 그의 제조법, 약물로서의 그의 용도, 및 ｍｅｔ 억제제로서의 그의 용도
ARP100100316A AR075248A1 (es) 2009-02-06 2010-02-05 Derivados de 6-(6-o-cicloalquil o de 6-nh-cicloalquil-triazolopiridazina-sulfanil) benzotiazoles y bencimidazoles: preparacion, aplicacion como medicamentos y utilizacion como inhibidores de la met.
TW099103558A TW201040187A (en) 2009-02-06 2010-02-05 6-(6-o-cycloalkyl-or 6-NH-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazole and benzimidazole derivatives: preparation, and use as medicaments and as MET inhibitors
UY0001032419A UY32419A (es) 2009-02-06 2010-02-05 Derivados de 6-(6-o-cicloalquil o de 6-nh-cicloalquil-triazolopiridazina-sulfanil) benzotiazoles y bencimidazoles: preparacion, aplicacion como medicamentos y utilizacion como inhibidores de la met
IL214407A IL214407A0 (en) 2009-02-06 2011-08-02 Derivatives of 6-(6-o-cycloalkyl or 6-nh-cycloalkyl-triazolopyridazine-sulfanyl)benzothiazoles and benzoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
CO11099121A CO6400222A2 (es) 2009-02-06 2011-08-05 Derivados de 6-(6-o-cicloalquil o de 6-nh-cicloalquil-triazolopiridazina-sulfanil) benzotiazoles y bencimidazoles:preparación, aplicación como medicamentos y utilización como inhibidores de la met

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0900510A FR2941949B1 (fr) 2009-02-06 2009-02-06 Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.

Publications (2)

Publication Number Publication Date
FR2941949A1 FR2941949A1 (fr) 2010-08-13
FR2941949B1 true FR2941949B1 (fr) 2011-04-01

Family

ID=40863635

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0900510A Expired - Fee Related FR2941949B1 (fr) 2009-02-06 2009-02-06 Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.

Country Status (18)

Country Link
EP (1) EP2393790A1 (ko)
JP (1) JP2012517407A (ko)
KR (1) KR20110126660A (ko)
CN (1) CN102388029A (ko)
AR (1) AR075248A1 (ko)
AU (1) AU2010212231A1 (ko)
BR (1) BRPI1011354A2 (ko)
CA (1) CA2751525A1 (ko)
CO (1) CO6400222A2 (ko)
EA (1) EA201171010A1 (ko)
FR (1) FR2941949B1 (ko)
IL (1) IL214407A0 (ko)
MA (1) MA33102B1 (ko)
MX (1) MX2011008312A (ko)
SG (1) SG173558A1 (ko)
TW (1) TW201040187A (ko)
UY (1) UY32419A (ko)
WO (1) WO2010089506A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1298125A1 (en) 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
WO2007064797A2 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
CN101360748B (zh) * 2005-11-30 2012-05-30 沃泰克斯药物股份有限公司 c-MET抑制剂及其应用
PL1966214T3 (pl) * 2005-12-21 2017-04-28 Janssen Pharmaceutica N.V. Triazolopirydazyny jako modulatory kinazy tyrozynowej
JP2009538899A (ja) * 2006-05-30 2009-11-12 ファイザー・プロダクツ・インク トリアゾロピリダジン誘導体
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
BRPI0717320A2 (pt) * 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Triazóis bicíclicos como moduladores de proteína cinase
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.

Also Published As

Publication number Publication date
SG173558A1 (en) 2011-09-29
EA201171010A1 (ru) 2012-03-30
BRPI1011354A2 (pt) 2019-09-24
WO2010089506A1 (fr) 2010-08-12
AU2010212231A1 (en) 2011-08-25
CA2751525A1 (fr) 2010-08-12
JP2012517407A (ja) 2012-08-02
MX2011008312A (es) 2011-11-02
CN102388029A (zh) 2012-03-21
MA33102B1 (fr) 2012-03-01
AR075248A1 (es) 2011-03-16
TW201040187A (en) 2010-11-16
IL214407A0 (en) 2011-09-27
FR2941949A1 (fr) 2010-08-13
CO6400222A2 (es) 2012-03-15
KR20110126660A (ko) 2011-11-23
EP2393790A1 (fr) 2011-12-14
UY32419A (es) 2010-09-30

Similar Documents

Publication Publication Date Title
BR112012013175A2 (pt) 2-amino-5,5-diflúor-5,6-di-hidro-4h-oxazinas como inibidores de bace 1 e/ou bace 2
BR112012026737A2 (pt) composição aquosa de revestimento, método de revestimento de um artigo ou estrutura e artigo ou estrutura
HK1164876A1 (en) 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
BRPI1014582A2 (pt) benzimidazois, benzotiazois e benzoxazoles substituidos
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
DOP2011000397A (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
BRPI1010649A2 (pt) benzimidazóis, benzotiazóis e benzoxazoles substituídos.
BR112012003152A2 (pt) composição removedora de oxigênio, artigo,e, uso de composição removedora de oxigênio.
IL251177B (en) Parasitic preparations containing benzaimidazole history, methods and uses
FR2941952B1 (fr) Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
BRPI1009375A2 (pt) derivados inibidores de hsp90, composições que os contém e utilização
FR2941951B1 (fr) Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
BR112013009640A2 (pt) derivados de tetrahidroquinolina usados como ativadores de ampk
FR2941949B1 (fr) Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FI20105730A0 (fi) Menetelmä c-puristimen rungon valmistamiseksi, c-puristimen runko ja c-puristin
BR112012018072A2 (pt) formulação anidra, método e utilização da formulação
FR2966151B1 (fr) Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
HK1188565A1 (en) Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans
FR2919870B1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
FR2934997B1 (fr) Derives cyclopropyl-et cyclobutyl-dioxazaborocanes ou dioxazaborecanes
BR112012001229A2 (pt) formulação farmacêutica aquosa, uso da formulação farmacêutica aquosa
FR2929613B1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
TH116167B (th) อนุพันธ์เบนซอกซาซีนเบนซิมิดาโซลใหม่, องค์ประกอบทางเภสัชกรรมซึ่งประกอบรวมด้วยสิ่งที่เหมือนกัน, และการใช้ของสิ่งนั้น
TH148532B (th) สูตรผสมสำหรับการรักษาระยะยาวของการติดเชื้อเอชไอวี

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20131031